MX358711B - Inmunogenos para vacunacion contra vih. - Google Patents

Inmunogenos para vacunacion contra vih.

Info

Publication number
MX358711B
MX358711B MX2014009091A MX2014009091A MX358711B MX 358711 B MX358711 B MX 358711B MX 2014009091 A MX2014009091 A MX 2014009091A MX 2014009091 A MX2014009091 A MX 2014009091A MX 358711 B MX358711 B MX 358711B
Authority
MX
Mexico
Prior art keywords
immunogens
relates
hiv vaccination
vaccination
hiv
Prior art date
Application number
MX2014009091A
Other languages
English (en)
Spanish (es)
Other versions
MX2014009091A (es
Inventor
Brander Christian
Mothe Pujadas Beatriz
Llano Anuska
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MX2014009091A publication Critical patent/MX2014009091A/es
Publication of MX358711B publication Critical patent/MX358711B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014009091A 2012-01-27 2013-01-28 Inmunogenos para vacunacion contra vih. MX358711B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382031.8A EP2620446A1 (en) 2012-01-27 2012-01-27 Immunogens for HIV vaccination
PCT/EP2013/051596 WO2013110818A2 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Publications (2)

Publication Number Publication Date
MX2014009091A MX2014009091A (es) 2014-11-10
MX358711B true MX358711B (es) 2018-08-31

Family

ID=47603800

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014009091A MX358711B (es) 2012-01-27 2013-01-28 Inmunogenos para vacunacion contra vih.
MX2018010483A MX2018010483A (es) 2012-01-27 2014-07-25 Inmunogenos para vacunacion contra vih.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018010483A MX2018010483A (es) 2012-01-27 2014-07-25 Inmunogenos para vacunacion contra vih.

Country Status (16)

Country Link
US (4) US9988425B2 (enExample)
EP (3) EP2620446A1 (enExample)
JP (2) JP6306514B2 (enExample)
KR (2) KR102140778B1 (enExample)
CN (2) CN104080800B (enExample)
AU (2) AU2013213564B2 (enExample)
BR (1) BR112014018396B1 (enExample)
CA (1) CA2862172C (enExample)
ES (1) ES2932407T3 (enExample)
IL (2) IL233771B (enExample)
IN (1) IN2014DN06164A (enExample)
MX (2) MX358711B (enExample)
NZ (3) NZ628756A (enExample)
RU (2) RU2648791C2 (enExample)
WO (1) WO2013110818A2 (enExample)
ZA (1) ZA201405204B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EA026557B1 (ru) 2008-12-09 2017-04-28 Джилид Сайэнс, Инк. Промежуточные соединения для получения модуляторов толл-подобных рецепторов
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CA2943478A1 (en) * 2014-03-21 2015-09-24 Nutech Ventures A non-naturally occuring porcine reproductive and respiratory syndrome virus (prrsv) and methods of using
PT3166607T (pt) 2014-07-11 2022-12-07 Gilead Sciences Inc Moduladores de receptores de tipo toll para o tratamento do vih
AU2015318061B2 (en) 2014-09-16 2018-05-17 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2020234839A1 (en) 2019-05-22 2020-11-26 Aelix Therapeutics, S.L. Dosage regimens for vaccines
AU2020280040A1 (en) * 2019-05-22 2022-01-20 Aelix Therapeutics S.L. Combination of a TLR7 modulating compound and an HIV vaccine
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
CN116322757A (zh) * 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案
US20210353744A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines Prevention B.V. Administration of homologous adenoviral vectors
WO2022084333A1 (en) 2020-10-20 2022-04-28 Janssen Vaccines & Prevention B.V. Hiv vaccine regimens
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
EP4417974A1 (en) 2023-02-17 2024-08-21 Fundació Privada Institut de Recerca de la SIDA-Caixa Cd33 as a biomarker of hiv control
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US6858712B1 (en) 1984-08-22 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Cloning and expression of HTLV-III DNA
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en) 1992-09-16 2008-01-15 Board Of Regents, The University Of Texas System Compositions and methods for eliciting immune or anti-infective responses
CA2164818C (en) 1993-06-09 2003-09-23 Charles D.Y. Sia Tandem synthetic hiv-1 peptides
DK0799058T3 (da) 1994-12-24 2003-11-24 Univ Cambridge Tech Forbedringer af eller med hensyn til endometriefunktion
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
CN1233187A (zh) 1996-08-09 1999-10-27 病毒技术公司 HIVp－17肽片段、含有该片段的组合物及其制造和使用方法
US6031647A (en) 1996-10-23 2000-02-29 Nortel Networks Corporation Stable power control for optical transmission systems
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
AU784679B2 (en) 1999-12-23 2006-05-25 International Aids Vaccine Initiative Improvements in or relating to immune responses to HIV
FR2803307A1 (fr) 1999-12-30 2001-07-06 Centre Nat Rech Scient Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1312275A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸
AU2001259291B2 (en) 2000-04-28 2006-11-23 Aventis Pasteur Limited Improved immunogenicity using a combination of DNA and vaccinia virus vector vaccines
DE60026199T2 (de) 2000-05-18 2006-11-23 Geneart Ag Synthetische Gene für gagpol und deren Verwendungen
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
EP2302059A1 (en) 2000-08-14 2011-03-30 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization
BRPI0115533B8 (pt) 2000-11-23 2021-05-25 Bavarian Nordic As variação do vírus vaccinia ankara modificado
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
EP2322626A1 (en) 2001-09-20 2011-05-18 Glaxo Group Limited HIV-GAG codon-optimised DNA vaccines
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
WO2003080112A2 (en) 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
RU2238946C2 (ru) * 2002-04-22 2004-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci
US7550147B2 (en) 2002-05-16 2009-06-23 Bavarian Nordic A/S Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA)
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
DE60323407D1 (de) 2002-05-16 2008-10-16 Bavarian Nordic As Fusionsprotein des regulatorische/akzessorische HIV Proteine
WO2004002415A2 (en) 2002-06-27 2004-01-08 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
BRPI0411127A (pt) * 2003-06-10 2006-05-23 Univ Melbourne composição de matéria para modulação de resposta imuno num sujeito a um antìgeno alvo e respectivos método de modulação, processo de produção de células de apresentação de antìgeno e método de tratamento e/ou profilaxia de doença ou condição associada à presença de antìgeno alvo de interesse
CN1852734B (zh) 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory IMPROVED MVA VACCINES
JP2007534302A (ja) * 2003-09-24 2007-11-29 オクソン セラピュティクス リミテッド Ｈｉｖ医薬
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
WO2005047483A2 (en) 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
WO2006010106A2 (en) * 2004-07-09 2006-01-26 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Dna-based vaccination of retroviral-infected individuals undergoing treatment
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
ES2539010T3 (es) 2004-08-27 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en) 2004-10-29 2006-07-20 Microsoft Corporation Association-based epitome design
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
WO2006123256A2 (en) 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
UA97800C2 (uk) 2006-03-10 2012-03-26 Пептселл Лімітед Пептидні послідовності і композиції
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
EP2023954B1 (en) 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunological composition
CN106148288A (zh) 2006-08-25 2016-11-23 美国国有健康与人类服务部(马里兰州) 重组修饰的安卡拉痘苗病毒及其应用、质粒载体及其应用
WO2008117813A1 (ja) 2007-03-28 2008-10-02 Hiroshima University ニワトリ胚性幹細胞およびその評価方法
WO2008134068A2 (en) * 2007-04-26 2008-11-06 Hawaii Biotech, Inc. Synthetic expression vectors for insect cells
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
CA2711145A1 (en) 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
BRPI0915915A2 (pt) * 2008-07-16 2019-09-24 Baylor Res Institute vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
US8709775B2 (en) 2008-08-29 2014-04-29 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
NZ593598A (en) * 2008-11-18 2013-02-22 Beth Israel Hospital Optimized antiviral vaccines with improved cellular immunogenicity
US20120308593A1 (en) 2009-09-17 2012-12-06 Sanofi Pasteur, Inc. Immunological Compositions for HIV
AU2010305030A1 (en) * 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
EP2488649B1 (en) 2009-10-16 2019-04-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
WO2011082422A2 (en) 2010-01-04 2011-07-07 The Johns Hopkins University Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
JP2014505462A (ja) 2010-11-10 2014-03-06 ラボラトリオス・デル・ドクター・エステベ・ソシエテ・アノニム 高免疫原性のｈｉｖｐ２４配列
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2020234839A1 (en) 2019-05-22 2020-11-26 Aelix Therapeutics, S.L. Dosage regimens for vaccines
AU2020280040A1 (en) 2019-05-22 2022-01-20 Aelix Therapeutics S.L. Combination of a TLR7 modulating compound and an HIV vaccine
CN116322757A (zh) 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案

Also Published As

Publication number Publication date
KR102140778B1 (ko) 2020-08-06
US20190055289A1 (en) 2019-02-21
CN104080800A (zh) 2014-10-01
US20180170971A1 (en) 2018-06-21
CA2862172C (en) 2023-07-18
RU2018104969A3 (enExample) 2019-02-22
KR20140122735A (ko) 2014-10-20
JP2018102314A (ja) 2018-07-05
AU2018203264A1 (en) 2018-05-31
AU2013213564B2 (en) 2018-03-29
EP4163290A1 (en) 2023-04-12
NZ628756A (en) 2016-12-23
US20150050310A1 (en) 2015-02-19
MX2018010483A (es) 2020-09-02
US9988425B2 (en) 2018-06-05
RU2018104969A (ru) 2019-02-22
NZ734689A (en) 2022-09-30
HK1204632A1 (en) 2015-11-27
EP2807185B1 (en) 2022-09-14
CN104080800B (zh) 2019-08-27
WO2013110818A2 (en) 2013-08-01
BR112014018396A8 (pt) 2017-07-11
US20210246172A1 (en) 2021-08-12
BR112014018396A2 (enExample) 2017-06-20
EP2807185A2 (en) 2014-12-03
US11325946B2 (en) 2022-05-10
KR102108149B1 (ko) 2020-05-12
RU2014135053A (ru) 2016-03-27
JP6306514B2 (ja) 2018-04-04
EP2620446A1 (en) 2013-07-31
NZ723229A (en) 2019-03-29
IN2014DN06164A (enExample) 2015-08-21
AU2018203264B2 (en) 2019-07-11
RU2721274C2 (ru) 2020-05-18
IL233771B (en) 2019-08-29
JP2015509707A (ja) 2015-04-02
BR112014018396B1 (pt) 2023-03-21
JP6749357B2 (ja) 2020-09-02
MX2014009091A (es) 2014-11-10
RU2648791C2 (ru) 2018-04-02
IL268629B (en) 2021-06-30
ES2932407T3 (es) 2023-01-18
IL268629A (en) 2019-10-31
US11919926B2 (en) 2024-03-05
AU2013213564A1 (en) 2014-09-04
CN110372798A (zh) 2019-10-25
US10815278B2 (en) 2020-10-27
CA2862172A1 (en) 2013-08-01
KR20190085552A (ko) 2019-07-18
WO2013110818A3 (en) 2013-11-07
ZA201405204B (en) 2015-10-28
IL233771A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
MX2020006117A (es) Integracion dirigida de acidos nucleicos.
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
EP3741848A3 (en) Protease variants and polynucleotides encoding same
SG10201900948PA (en) Modified nucleotide linkers
PH12015501526B1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
GB201009222D0 (en) Improved cancer therapy based on tumour associated antigens derived from cyclin D1
EP3741849A3 (en) Protease variants and polynucleotides encoding same
IL236650B (en) Immunogenic combination, nucleic acids or vectors encoding it, host cells or compositions comprising them, and therapeutic uses thereof, process of producing an infectious virus and method for recombinant production of the mycobacterial antigens
PH12016500500A1 (en) A viral vaccine and methods of manufacture thereof
WO2016046234A3 (en) Recombinant phe-free proteins for use in the treatment of phenylketonuria
GB0917002D0 (en) Improved shigella blebs
MX2013004892A (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
WO2015052543A3 (en) Malaria vaccination
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
WO2014017493A9 (ja) ワクチン
GB201017519D0 (en) Vaccines
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
PH12015502353A1 (en) Fusion polypeptides and vaccines
MX363149B (es) Vacunas de nucleoproteina de la influenza.
MX2016012840A (es) Moléculas para transporte de antígeno modular mejoradas y sus usos.
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MX2019007924A (es) Vacunas contra la influenza.
WO2015070207A3 (en) Ama-1 epitopes, antibodies, compositions, and methods of making and using the same

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA -

FG Grant or registration
HC Change of company name or juridical status

Owner name: FUNDACION PRIVADA INSTITUT DE RECERCA DE LA SIDA -